Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Bristol-Myers Discloses Prelim. $6.29 GAAP & Non-GAAP EPS Impact For 3 Months Ended March 31 Related To Acquired IPRD & Licensing Income

Author: Benzinga Newsdesk | April 24, 2024 09:41am

Posted In: BMY